Antisense & RNAi Therapeutics Market Report 2026

Antisense & RNAi Therapeutics Market Overview

• Antisense & RNAi Therapeutics market size has reached to $1.93 billion in 2025 • Expected to grow to $3.53 billion in 2030 at a compound annual growth rate (CAGR) of 12.9% • Growth Driver: Emerging Demand Antisense & RNAI Therapeutics For Neurodegenerative Disorders And Infectious Diseases • Market Trend: Strategic Collaborations Driving Innovation In The Antisense & RNAI Therapeutics Market • North America was the largest region in 2025.

What Is Covered Under Antisense & RNAi Therapeutics Market?

Antisense therapy refers to the selective, sequence-specific suppression of gene expression by single-stranded DNA oligonucleotides. Contrarily, RNA interference (RNAi) is activated by double-stranded RNA (dsRNA) and results in the sequence-specific mRNA degradation of single-stranded target RNAs. The main technologies of antisense & RNAi therapeutics are RNA interference and antisense RNA. RNA interference is a conserved biological response to double-stranded RNA that mediates resistance to both endogenous parasitic and exogenous pathogenic nucleic acids and regulates protein-coding gene expression. The various routes of administration include pulmonary delivery, intravenous injections, intra-dermal injections, intraperitoneal injections, topical delivery, and other delivery methods that are used for the indication of oncology, cardiovascular diseases (CVDs), respiratory disorders, neurological disorders, infectious diseases, other.

What Is The Antisense & RNAi Therapeutics Market Growth Forecast?

The antisense & rnai therapeutics market size is expected to see rapid growth in the next few years. It will grow to $3.53 billion in 2030 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to advancements in delivery technologies, expansion of precision medicine, integration with ai-driven drug discovery, increasing rnai-based clinical trials, rising healthcare investments in emerging markets. Major trends in the forecast period include targeted gene silencing, novel delivery mechanisms, personalized therapeutics, nucleic acid stabilization techniques, regulatory & clinical advancements.

Global Antisense & RNAi Therapeutics Market Segmentation

1) By Technology: RNA Interference, Antisense RNA 2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods 3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications Subsegments: 1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), Short Hairpin RNA (shRNA), Dicer-substrate siRNA, MicroRNA (miRNA) Based Therapeutics 2) By Antisense RNA: Antisense Oligonucleotides (ASOs), Morpholino Oligomers, Locked Nucleic Acids (LNAs), Gapmer Antisense Oligonucleotides

What Is The Driver Of The Antisense & RNAi Therapeutics Market?

The rising prevalence of coronary artery diseases, neurodegenerative disorders, and infectious diseases is projected to contribute to the demand for the antisense & RNAi therapeutics market. Gene suppression approaches including RNA interference and antisense oligonucleotides are used for the treatment of various neurodegenerative conditions by repairing mutant genes. For instance, in January 2024, according to the report published by the American Heart Association, a US-based organization, the age-adjusted death rate from cardiovascular diseases increased to 233.3 per 100,000, reflecting a 4.0% rise from the previous year. Hence, the growing prevalence of several neurodegenerative diseases and infectious diseases is expected to drive the growth of the antisense & RNAi therapeutics industry.

Key Players In The Global Antisense & RNAi Therapeutics Market

Major companies operating in the antisense & rnai therapeutics market are Biogen Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Moderna Inc., Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd, Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline Plc, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics, Dynacure, CN Bio Innovations, Sarepta Therapeutics, Mallinckrodt, Regeneron Pharmaceuticals Inc., Alcyone Lifesciences Inc., Bio-Path Holdings Inc, Calando Pharmaceuticals, Enzon Pharmaceuticals Inc, Celnova Pharma, Pfizer Inc., Taiba Pharma, Gen İlaç ve Sağlık Ürünleri A.Ş., Egypt Otsuka Pharmaceutical

Global Antisense & RNAi Therapeutics Market Trends and Insights

Major companies operating in the antisense & RNAi therapeutics market are undertaking strategic initiatives, such as collaborations and partnerships to sustain in the increasingly competitive market. Strategic collaboration is a business strategy that involves two or more companies working together to achieve a common goal or objective. For instance, in January 2023, Orbit Discovery Limited, a US-based company offering services for the discovery of peptides, partnered with SanegeneBio Inc., a UK-based company involved in the developing novel RNAi-based medicines for the identification of tissue-specific delivery of RNA therapeutics for efficient gene knockdown, aiming to develop a portfolio of advanced RNAi therapeutics. The collaboration encompasses hit identification and cell-based internalization studies, with Sanegene having the option to further develop the hits derived from the screening activities, leveraging Orbit's proprietary technology for rapid peptide lead discovery. Orbit Discovery's unique peptide display engine enables the screening of large peptide libraries, offering faster discovery times for relevant peptide leads based on affinity and functional screens.

What Are Latest Mergers And Acquisitions In The Antisense & RNAi Therapeutics Market?

In July 2023, Alnylam, a US-based biopharmaceutical company that specializes in RNAi therapeutics, announced a strategic partnership with Roche AG to co-develop and co-commercialize Zilebesiran, an investigational RNAi therapeutic for the treatment of hypertension in patients with high cardiovascular risk. This collaboration combines Alnylam's expertise in RNAi therapeutics with Roche's extensive experience in drug development and commercialization, potentially transforming treatment options for patients with hypertension and high cardiovascular risk. Roche AG is a Switzerland-based pharmaceutical company that specializes in therapeutic treatment of cardiovascular diseases.

Regional Insights

North America was the largest region in the antisense & RNAi therapeutics market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Antisense & RNAi Therapeutics Market?

The antisense and RNAi therapeutics market includes revenues earned by entities by regulating gene expression at multiple levels, such as replication, transcription, and translation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Antisense & RNAi Therapeutics Market Report 2026?

The antisense & rnai therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the antisense & rnai therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.